Restoring health by delivering first-in-class therapeutics that harness alternative splicing.

Biosplice is a biopharmaceutical company developing first-in-class, small-molecule therapeutics based on pioneering science of RNA alternative splicing. The company's scientific platform is based on biological discoveries that govern tissue specialization and enable elimination of harmful proteins using these small molecules. Biosplice's clinical pipeline is focused on osteoarthritis and oncology, with a lead indication in knee osteoarthritis and early-stage programs in oncology and neurology and other areas of significant unmet medical need.